Alnylam Reports Results of Lumasiran in P-III ILLUMINATE-B Study for Primary Hyperoxaluria Type 1 in Children Under the Age of Six

October 1, 2020 Auto Bot Alnylam, Clinical Trials, P-III study, reports, results 0

Shots:

  • The P-III ILLUMINATE-B study involves assessing Lumasiran in 18 patients with PH1 under the age of 6 (3-72mos.), with an eGFR >45 mL/min/1.73 m2 or normal serum creatinine if less than 12mos. old at 9 study sites in 5 countries across the globe
  • The study demonstrated a reduction in the hepatic production of oxalate across all ages, safety & tolerability profile is consistent with that observed in P-III ILLUMINATE-A study. The study also demonstrated positive results across 2EPs, including additional measures of urinary and plasma oxalate
  • Lumasiran (SC) RNAi therapeutic targeting HAO1 in development for the treatment of PH1 and has received the US FDA’s ODD & BT in addition to EMA’s ODD and PRIME designation

Click here ­to­ read full press release/ article | Ref: Alnylam | Image: Alnylam

The post Alnylam Reports Results of Lumasiran in P-III ILLUMINATE-B Study for Primary Hyperoxaluria Type 1 in Children Under the Age of Six first appeared on PharmaShots.